Abstract 3930
Background
Tepotinib is an oral, selective, potent MET tyrosine kinase inhibitor, with promising clinical activity in patients (pts) with MET+ tumors, being tested in NSCLC harboring METex14 mutations or MET amplification. We aimed to further characterize the safety profile of tepotinib.
Methods
Safety data from pts receiving tepotinib 500 mg once daily (QD) from five studies (NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992) were pooled and summarized. Pts received tepotinib until disease progression, intolerable toxicity, or other withdrawal. Adverse events (AEs) were graded by NCI CTCAE v4.03.
Results
As of 9/28/2018, 422 pts had received tepotinib; 228 received 500 mg tepotinib monotherapy QD and were further analyzed for safety (73.2% male, 50.9%/35.5% white/Asian, median age 65.0 [range 19–89] yrs). Median treatment duration was 2.7 months (range 0.0–21.5); in NSCLC pts with METex14 mutations it was 4.1 months (NCT02864992). 219 pts (96.1%) had an AE (any cause). 122 pts (53.5%) had a Grade ≥3 any cause AE including (>3.5%): disease progression (n = 18, 7.9%), hyponatremia (n = 12, 5.3%), increased aspartate aminotransferase (AST) (n = 12, 5.3%), increased lipase (n = 11, 4.8%), peripheral edema (n = 9, 3.9%) and ascites (n = 9, 3.9%). The incidence rates were: 19.0, 12.9, 12.9, 12.0, 9.6 and 9.6 per 100 pt-years, respectively. Treatment-related (TR)AEs are shown in the Table. 18 pts (7.9%) had a serious TRAE including (≥1%) peripheral edema (n = 4, 1.8%). AEs (any cause) led to dose reduction of tepotinib in 33 pts (14.5%) and discontinuation in 49 pts (21.5%), and was due to peripheral edema in 5 (8.5%) and 7 (3.1%) pts, respectively. Of 25 AEs leading to death, two were considered treatment related by the investigator (upper GI hemorrhage and hypoglycemic coma).
Conclusions
Tepotinib demonstrated an acceptable safety profile across a range of tumor types and is being developed in NSCLC as monotherapy and in combination. Further characterization of peripheral edema is ongoing.Table:
479P
N = 228 | ||
---|---|---|
Any Grade (≥10%) | Grade ≥3 (≥2%) | |
Any TRAE, n (%) | 172 (75.4) | 52 (22.8) |
Peripheral edema | 77 (33.8) | 8 (3.5) |
Diarrhea | 45 (19.7) | 4 (1.8) |
Fatigue | 34 (14.9) | 3 (1.3) |
Nausea | 29 (12.7) | 0 (0) |
Decreased appetite | 27 (11.8) | 0 (0) |
Increased lipase | 13 (5.7) | 9 (3.9) |
Increased AST | 11 (4.8) | 5 (2.2) |
Clinical trial identification
NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.
Editorial acknowledgement
Medical writing assistance (funded by Merck Healthcare KGaA, Darmstadt, Germany) was provided by Matthew deSchoolmeester, PhD of Bioscript Science (Macclesfield, UK).
Legal entity responsible for the study
Merck KGaA.
Funding
Merck KGaA.
Disclosure
T. Decaens: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy: IPSEN; Honoraria (self), Travel / Accommodation / Expenses: Gilead; Honoraria (self), Travel / Accommodation / Expenses: Abbvie; Honoraria (self): Sanofi; Advisory / Consultancy: SITEX; Research grant / Funding (institution): ArQule; Research grant / Funding (institution): Genoscience Pharma; Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Merck Serono; Advisory / Consultancy: BTG; Advisory / Consultancy: Sirtex. R. Veillon: Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Novartis; Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Merck. K. Yamazaki: Honoraria (self): Chugai; Honoraria (self): Takeda; Honoraria (self): Yakult; Honoraria (self): Daiichi‐sankyo; Honoraria (self): Merck Serono; Honoraria (self): Bristol; Honoraria (self): Bayer; Honoraria (self): Eli Lilly; Honoraria (self): Taiho; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Sanofi. J. Scheele: Full / Part-time employment: Merck KGaA. R. Bruns: Full / Part-time employment: Merck KGaA. K. Berghoff: Full / Part-time employment: Merck KGaA. S. Faivre: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Blueprint; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer Pharma; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis. P.P. Paik: Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Abbvie; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Celgene; Research grant / Funding (institution), Travel / Accommodation / Expenses: EMD Serono; Honoraria (self): Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract